© 2017 Pharmstandard Ventures
Proteon Therapeutics
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
IPO in October, 2014
Proteon Therapeutics
(NASDAQ:PRTO)
Waltham, MA, USA
Year of Investment: 2014
IPO in October, 2014
Proteon Therapeutics Inc. is a biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. Proteon's first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls, thus improving the maturation, patency and life of arteriovenous fistula in hemodialysis patients.

For more information, please visit:

www.proteontherapeutics.com

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally